Weidmann P, de Courten M, Boehlen L, Shaw S
Medizinische Poliklinik, University of Berne, Switzerland.
Drugs. 1993;46 Suppl 2:197-208; discussion 208-9. doi: 10.2165/00003495-199300462-00030.
Obese subjects are at an increased risk of becoming hypertensive and vice versa. Essential hypertension and obesity are commonly accompanied by insulin resistance (defined as impaired insulin-mediated glucose disposal) and hyperinsulinaemia. In the offspring of patients with essential hypertension, insulin resistance and hyperinsulinaemia, as well as related increases in serum low density lipoproteins and triglycerides, often occur prior to the development of essential hypertension, overweight or central redistribution of body fat. Moreover, once obesity, and in particular central obesity, is present, insulin resistance is more marked in hypertensive than in normotensive obese subjects. Hyperinsulinaemia and/or insulin resistance in turn promote body fat deposition and impaired glucose tolerance. This cycle helps to explain why a familial predisposition to essential hypertension poses an increased risk of developing not only hypertension but also dyslipidaemia, obesity and non-insulin-dependent (type 2) diabetes. It is still unclear whether insulin resistance and/or hyperinsulinaemia also promote hypertension per se. Regardless of insulin's exact pathogenic role, obesity and/or a high dietary intake of carbohydrates, salt, etc. can induce several potential pressor mechanisms: 1) higher plasma noradrenaline (norepinephrine) and adrenaline (epinephrine) levels, suggesting a higher sympathetic tone in obese than in nonobese subjects, and in hypertensive obese than in normotensive obese subjects; 2) similarly, a tendency to hyperaldosteronism, with largely normal plasma renin activity, in obese hypertensive patients; 3) enhanced sensitivity of blood pressure to salt; 4) increased total blood volume (although it is normal relative to body surface area), leading to increased cardiac output and eventually eccentric left ventricular hypertrophy; and 5) increased cytosolic free Ca++ levels and reduced intracellular Mg++ levels in the blood cells of obese hypertensive patients and patients with non-insulin-dependent diabetes, although this finding cannot necessarily be extrapolated to cationic levels in vascular muscle cells. Total peripheral vascular resistance is usually low in normotensive obese subjects and rises with the development of hypertension; compared with lean patients with essential hypertension, obese hypertensive patients tend to have a slightly lower level of total peripheral vasoconstriction and a slightly higher cardiac output. Considering the intimate association between essential hypertension and obesity, as well as the prevalence and prognostic relevance of this combination, the spectrum of accompanying metabolic and cardiovascular abnormalities deserves careful consideration in the evaluation of therapeutic care for such patients.
肥胖个体患高血压的风险增加,反之亦然。原发性高血压和肥胖通常伴有胰岛素抵抗(定义为胰岛素介导的葡萄糖代谢受损)和高胰岛素血症。在原发性高血压患者的后代中,胰岛素抵抗、高胰岛素血症以及血清低密度脂蛋白和甘油三酯的相关升高,往往在原发性高血压、超重或体脂中心分布出现之前就已发生。此外,一旦出现肥胖,尤其是中心性肥胖,高血压肥胖患者的胰岛素抵抗比血压正常的肥胖患者更为明显。高胰岛素血症和/或胰岛素抵抗反过来又会促进体脂沉积和葡萄糖耐量受损。这个循环有助于解释为什么原发性高血压的家族易感性不仅会增加患高血压的风险,还会增加患血脂异常、肥胖和非胰岛素依赖型(2型)糖尿病的风险。目前尚不清楚胰岛素抵抗和/或高胰岛素血症是否也会直接促进高血压的发生。无论胰岛素的确切致病作用如何,肥胖和/或高碳水化合物、高盐饮食等都可能引发多种潜在的升压机制:1)血浆去甲肾上腺素(norepinephrine)和肾上腺素(epinephrine)水平升高,表明肥胖个体比非肥胖个体交感神经张力更高,高血压肥胖患者比血压正常的肥胖患者交感神经张力更高;2)同样,肥胖高血压患者有醛固酮增多症的倾向,而血浆肾素活性大多正常;3)血压对盐的敏感性增强;4)总血容量增加(尽管相对于体表面积是正常的),导致心输出量增加,最终导致离心性左心室肥厚;5)肥胖高血压患者和非胰岛素依赖型糖尿病患者血细胞中的胞浆游离Ca++水平升高,细胞内Mg++水平降低,尽管这一发现不一定能外推到血管平滑肌细胞中的阳离子水平。血压正常的肥胖个体总外周血管阻力通常较低,随着高血压的发展而升高;与原发性高血压的瘦患者相比,肥胖高血压患者的总外周血管收缩水平略低,心输出量略高。考虑到原发性高血压与肥胖之间的密切关联,以及这种组合的患病率和预后相关性,在评估此类患者的治疗护理时,应仔细考虑伴随的代谢和心血管异常情况。